ERBB2 and breast cancer: Having confirmed PBMC function against aggregates of the two BC cell lines used, in the presence of anti-HER2 antibodies, we challenged the encapsulated 3D co-cultures with the antibody combination (trastuzumab plus pertuzumab) or trastuzumab alone and compared cancer and immune cell phenotype with untreated control.